
Opinion|Videos|May 1, 2025
Optimizing Genomic Testing in Breast Cancer: Strategies for Community Practitioners
Panelists discuss how community practitioners face challenges with genomic testing due to working across multiple hospitals with different medical oncology groups who may have varying preferences for assays, emphasizing the importance of communication, established algorithms, and leveraging partnerships with testing companies.
Advertisement
Practical Implementation and Community Practice Challenges
Main Discussion Topics:
- Challenges faced by community practitioners regarding genomic testing
- Implementation of reflex testing strategies based on pathological criteria
- Billing, reimbursement, and ordering logistics in different practice settings
Key Points for Physicians:
- Community practitioners often work across multiple hospitals with different medical oncology groups who may have different testing preferences.
- Electronic portal-based ordering systems and electronic medical record integration improve workflow efficiency.
- Relationships with testing companies can help address reimbursement and coding issues.
Notable Insights:
- Some institutions implement reflex testing criteria based on T and N staging and patient age to improve efficiency.
- Testing companies can be valuable partners in ensuring appropriate coding and test selection.
Clinical Significance: Successful implementation of genomic testing in community settings requires robust communication systems, clear algorithms, and attention to billing/reimbursement considerations to ensure appropriate test utilization.
Advertisement
Related to this article

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.

The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.

TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.

An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
3
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
4
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
5

